Medivation touts positive results of Alzheimer
Written on April 19, 2008
Medivation Inc. said its Alzheimer's drug Dimebon improved cognitive function in patients when compared with a placebo.
Data from a study of the drug were presented at a neurology conference in Chicago this week. Steven Ferris, a psychiatry professor at New York University, said the drug improved memory, orientation, language and praxis, or motor function. People treated with the drug needed less help from their caregivers than those on a placebo.
The drug was tested in a 183-patient trial in people with mild to moderate Alzheimer's.
Medivation plans to start a second Phase III trial of the drug in the second quarter of this year, and to apply for regulatory approval in the United States and Europe in 2010 http://savingpaydayloans.com. The same drug is being tested in a Phase II trial against Huntington's disease.
Medivation lost $31.7 million in 2007, twice what it lost in 2006.
The San Francisco company lost $15.4 million in 2006 and has lost a total of $60.2 million since its start in late 2003. New drug companies often run up large losses in their early years as they seek drug candidates, test them, and wait for regulatory approval.
David Hung, M.D., is president and CEO of Medivation (NASDAQ: MDVN).
Filed in: online.